Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Jul 25:10:862266.
doi: 10.3389/fpubh.2022.862266. eCollection 2022.

The promising role of probiotics/prebiotics/synbiotics in energy metabolism biomarkers in patients with NAFLD: A systematic review and meta-analysis

Shudi Li  1 , Jiangkai Liu  2 , Zhen Wang  2 , Fei Duan  2 , Zi Jia  1 , Xinju Chen  2 , Suling Li  2
Affiliations
Meta-Analysis

The promising role of probiotics/prebiotics/synbiotics in energy metabolism biomarkers in patients with NAFLD: A systematic review and meta-analysis

Shudi Li et al. Front Public Health. .

Abstract

Background: Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease with a high prevalence worldwide, seriously harming human health, and its pathogenesis remains unclear. In recent years, increasing evidence has indicated that intestinal microbiota plays an important role in the occurrence and development of NAFLD. The regulation method of probiotics/prebiotics/synbiotics can alter the intestinal microbiota and has been suggested as an option in the treatment of NAFLD.

Methods: Five databases of PubMed, Embase, the Cochrane Library, clinicaltrails.gov, and China National Knowledge Infrastructure were searched initially, and then the eligible studies were screened. Finally, the data of included studieswere extracted, combined and analyzed.

Results: A total of 29 randomized controlled trials involving 2,110 patients were included in this study. The results showed that using probiotics/prebiotics/synbiotics in the intervention group could reduce the levels of glucose (SMD = -0.23, 95% CI [-0.45, -0.01], P = 0.04), HOMA-IR (SMD = -0.47, 95% CI [-0.63, -0.31], P < 0.00001) and insulin (SMD = -0.46, 95% CI [-0.76, -0.16], P = 0.002) in sugar metabolism; in terms of lipid metabolism, the levels of TC (SMD = -0.62, 95%CI [-0.87, -0.36], P < 0.00001), and LDL-C (SMD = -0.57, 95%CI [-0.85, -0.28], P < 0.00001) were decreased; and the level of ALB was decreased in protein metabolism (SMD = -0.34, 95%CI [-0.61, -0.06], P = 0.02).

Conclusions: Based on the current evidence, probiotics/prebiotics/synbiotics may improve energy metabolism biomarkers in the NAFLD population, but these effects still need to be confirmed by further research.

Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/#aboutpage.

Keywords: NAFLD; energy metabolism biomarkers; microbiota modulation; prebiotics; probiotics; synbiotics.

PubMed Disclaimer

Figures

Figure 1
Figure 1
PRISMA flow diagram.
Figure 2
Figure 2
Risk-of-bias graph.
Figure 3
Figure 3
The role of PPS in Glucose in patients with NAFLD.
Figure 4
Figure 4
The role of PPS in HOMA-IR in patients with NAFLD.
Figure 5
Figure 5
The role of PPS in Insulin in patients with NAFLD.
Figure 6
Figure 6
The role of PPS in TC in patients with NAFLD.
Figure 7
Figure 7
The role of PPS in TG in patients with NAFLD.
Figure 8
Figure 8
The role of PPS in LDL-C in patients with NAFLD.
Figure 9
Figure 9
The role of PPS in HDL-C in patients with NAFLD.
Figure 10
Figure 10
The role of PPS in ALB in patients with NAFLD.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, et al. . The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. (2020) 14:889–919. 10.1007/s12072-020-10094-2 - DOI - PubMed
    1. Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastro Hepat. (2010) 7:195–203. 10.1038/nrgastro.2010.21 - DOI - PubMed
    1. Younossi ZM, Golabi P, de Avila L, Paik J. M., Srishord M., Fukui N., et al. . Global epidemiology of NAFLD and NASH in patients with type 2 diabetes:a systematic review and meta-analysis. J Hepatol. (2019) 71, 793–801. 10.1016/j.jhep.2019.06.021 - DOI - PubMed
    1. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease:old questions and new insights. Science. (2011) 332:1519–23. 10.1126/science.1204265 - DOI - PMC - PubMed
    1. Golabi P, Sayiner M, Fazel Y, Koenig A, Henry L, Younossi ZM, et al. . Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis. Expert Rev Gastroenterol Hepatol. (2016) 10:63. 10.1586/17474124.2016.1099433 - DOI - PubMed

Publication types